Company facts
- Industry
- Pharmaceutical Preparations
- Headquarters
- Boston, Massachusetts
- Most recent report
- 8-K, filed Aug 25, 2026
- Incorporated
- Delaware
- Filings on record
- 260 filings
- On EDGAR
- CIK 2023658
- Fiscal year ends
- December
- Filer status
- Emerging growth company
Financials 8
News 8 of 20
Prospectuses and Registrations 8 of 14
- S-8 Registration statement for an employee plan Aug 11, 2026
- S-8 Registration statement for an employee plan Mar 31, 2026
- 424B5 Prospectus supplement for an offering Feb 26, 2026
- FWP Free writing prospectus Feb 25, 2026
- 424B5 Prospectus supplement for an offering Feb 24, 2026
- 424B5 Prospectus supplement for an offering Nov 26, 2025
- S-3 Shelf registration statement Oct 3, 2025
- S-8 Registration statement for an employee plan Mar 28, 2025
Proxies 4
Ownership 8 of 193
- 144 Notice of a proposed sale of restricted stock Sep 8, 2026
- 144 Notice of a proposed sale of restricted stock Sep 8, 2026
- 4 Insider reported a trade Aug 14, 2026
- 3 Insider reported their initial holding Aug 14, 2026
- SCHEDULE 13G/A Large holder reported a passive stake, amended Aug 13, 2026
- 4 Insider reported a trade Aug 12, 2026
- 4 Insider reported a trade Aug 12, 2026
- 4 Insider reported a trade Aug 12, 2026
Other 8 of 21
- ARS Annual report sent to shareholders Apr 27, 2026
- EFFECT Notice that a registration became effective Nov 26, 2025
- CORRESP Reply to SEC staff Nov 24, 2025
- ARS Annual report sent to shareholders Apr 25, 2025
- SEC STAFF LETTER Sep 13, 2024
- EFFECT Notice that a registration became effective Sep 12, 2024
- S-1MEF Sep 12, 2024
- CERT Exchange certified a listing Sep 12, 2024
Everything here comes from Bicara Therapeutics Inc.'s own filings on SEC EDGAR. The filing list is rechecked every hour.